What is Palmitoylethanolamide (544-31-0)?

Palmitoylethanolamide (PEA), an endogenous (manufactured by the body) fatty acid amide, is emerging as a new agent in the treatment of pain and inflammation. As an endogenous agent and one also found in foods such as eggs and milk, no serious side effects or drug–drug interactions been identified. PEA has demonstrated effectiveness for chronic pain of multiple types associated with many painful conditions, especially with neuropathic (nerve) pain, inflammatory pain and visceral pain such as endometriosis and interstitial cystitis.To get more news about Palmitoylethanolamide (PEA), cofttek official website is the best place for you.
Palmitoylethanolamide (544-31-0) benefits

At first, it reduces, via the peroxisome proliferator-activated receptor alpha (PPARα), the recruitment and activation of mast cells at sites of nerve injury and the release of pro-inflammatory mediators from these cells; secondly, it inhibits the microglia activation and the recruitment of mast cells into spinal cord after peripheral nerve injury, as well as following spinal neuroinflammation or spinal cord injury.

Several studies focused on the use of PEA in a multitude of chronic pain conditions. For example, it can have a beneficial effect like adjuvant for the treatment of the low back pain or it was used alone for chronic pain management in critically ill older patients, where the use of traditional analgesics can lead to high risk of adverse effect. Encouraging results have been shown in the treatment of non-surgical radiculopathies with an ultra-micronized formulation of PEA and the combination therapy with alpha-lipoic acid to reduce chronic prostatitis/chronic pelvic pain syndrome.
_________________________
Supplement raw material manufacturer